Medicus Pharma (MDCX) Competitors $2.48 -0.07 (-2.75%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MDCX vs. SCLX, SLS, CHRS, CRBU, NLTX, ENTA, VTYX, MIST, BTMD, and JMACShould you be buying Medicus Pharma stock or one of its competitors? The main competitors of Medicus Pharma include Scilex (SCLX), SELLAS Life Sciences Group (SLS), Coherus Oncology (CHRS), Caribou Biosciences (CRBU), Neoleukin Therapeutics (NLTX), Enanta Pharmaceuticals (ENTA), Ventyx Biosciences (VTYX), Milestone Pharmaceuticals (MIST), biote (BTMD), and Maxpro Capital Acquisition (JMAC). These companies are all part of the "pharmaceutical products" industry. Medicus Pharma vs. Its Competitors Scilex SELLAS Life Sciences Group Coherus Oncology Caribou Biosciences Neoleukin Therapeutics Enanta Pharmaceuticals Ventyx Biosciences Milestone Pharmaceuticals biote Maxpro Capital Acquisition Scilex (NASDAQ:SCLX) and Medicus Pharma (NASDAQ:MDCX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership. Does the media favor SCLX or MDCX? In the previous week, Scilex had 7 more articles in the media than Medicus Pharma. MarketBeat recorded 13 mentions for Scilex and 6 mentions for Medicus Pharma. Scilex's average media sentiment score of 0.60 beat Medicus Pharma's score of 0.54 indicating that Scilex is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scilex 3 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Medicus Pharma 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in SCLX or MDCX? 69.7% of Scilex shares are owned by institutional investors. 7.9% of Scilex shares are owned by insiders. Comparatively, 11.2% of Medicus Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate SCLX or MDCX? Scilex presently has a consensus target price of $455.00, indicating a potential upside of 1,476.03%. Medicus Pharma has a consensus target price of $23.50, indicating a potential upside of 847.58%. Given Scilex's higher probable upside, equities analysts clearly believe Scilex is more favorable than Medicus Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scilex 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Medicus Pharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.20 Which has higher valuation and earnings, SCLX or MDCX? Medicus Pharma has lower revenue, but higher earnings than Scilex. Medicus Pharma is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScilex$56.59M3.55-$72.81M-$29.02-0.99Medicus PharmaN/AN/A-$11.16M-$1.34-1.85 Is SCLX or MDCX more profitable? Medicus Pharma has a net margin of 0.00% compared to Scilex's net margin of -179.12%. Scilex's return on equity of 0.00% beat Medicus Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Scilex-179.12% N/A -109.95% Medicus Pharma N/A -549.30%-228.06% SummaryScilex beats Medicus Pharma on 8 of the 14 factors compared between the two stocks. Get Medicus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDCX vs. The Competition Export to ExcelMetricMedicus PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$44.18M$3.07B$5.65B$10.29BDividend YieldN/A2.36%5.68%4.62%P/E Ratio-1.8520.7675.8426.11Price / SalesN/A403.84517.46171.31Price / CashN/A45.9137.5661.52Price / Book8.559.6212.876.30Net Income-$11.16M-$52.73M$3.29B$271.03M7 Day Performance2.06%0.64%-0.26%-0.15%1 Month Performance14.29%6.31%3.84%6.41%1 Year PerformanceN/A18.97%68.35%28.81% Medicus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDCXMedicus Pharma2.1225 of 5 stars$2.48-2.7%$23.50+847.6%N/A$44.18MN/A-1.85N/ANews CoverageSCLXScilex2.0766 of 5 stars$25.33+1.5%$455.00+1,696.3%-0.5%$176.20M$44.24M-0.8780News CoverageSLSSELLAS Life Sciences Group1.4361 of 5 stars$1.67-1.5%$7.00+320.4%+34.7%$175.32M$1M-5.2010CHRSCoherus Oncology4.3865 of 5 stars$1.48+9.3%$4.51+205.9%+58.0%$171.44M$272.21M0.95330Positive NewsCRBUCaribou Biosciences2.5985 of 5 stars$1.81+4.9%$6.67+269.3%+10.9%$168.08M$9.99M-1.01100News CoveragePositive NewsAnalyst RevisionNLTXNeoleukin TherapeuticsN/A$17.71+1.5%N/A-58.6%$166.44MN/A-5.6990High Trading VolumeENTAEnanta Pharmaceuticals4.0928 of 5 stars$7.75+2.8%$20.20+160.6%-28.3%$165.16M$67.64M-1.79160VTYXVentyx Biosciences2.5951 of 5 stars$2.32+0.2%$7.50+224.0%+11.8%$165.08MN/A-1.3830News CoveragePositive NewsMISTMilestone Pharmaceuticals2.6313 of 5 stars$1.94-0.3%$4.50+132.6%+26.0%$164.46M$1M-2.3030BTMDbiote2.9602 of 5 stars$3.32-0.3%$6.00+80.7%-48.6%$164.04M$197.19M3.69194News CoveragePositive NewsJMACMaxpro Capital AcquisitionN/A$12.18+31.1%N/AN/A$163.55MN/A0.002,021High Trading Volume Related Companies and Tools Related Companies Scilex Alternatives SELLAS Life Sciences Group Alternatives Coherus Oncology Alternatives Caribou Biosciences Alternatives Neoleukin Therapeutics Alternatives Enanta Pharmaceuticals Alternatives Ventyx Biosciences Alternatives Milestone Pharmaceuticals Alternatives biote Alternatives Maxpro Capital Acquisition Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDCX) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MDCX Stock Alerts